Story
Alnylam Stock Slides on Concerns Over Drug Class After AstraZeneca Trial Fails
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) fell by as much as 6% after a competitor's clinical trial failure raised investor concerns about an entire class of experimental therapies known as "silencer" drugs.
AstraZeneca's Trial Setback
The sell-off was triggered by news from AstraZeneca (NASDAQ:AZN), which on Friday detailed the failure of its Phase 3 clinical trial for an experimental silencer drug. The therapy was being tested for transthyretin amyloid cardiomyopathy (ATTR-CM), a progressive and serious heart condition.
According to a report from STAT News, the study showed that patients receiving AstraZeneca’s drug saw no improvement if they were already being treated with a standard-of-care medication known as a stabilizer. This effect was significant enough to cause the entire late-stage study to fail, as most participants were already on a stabilizer drug.
AdMarket-Wide Implications
AstraZeneca’s results have created a negative read-across for other companies developing similar treatments, including Alnylam. The failure raises broader questions about the efficacy of silencer drugs, particularly when used in combination with existing therapies.
The development casts a shadow over what is expected to become a multi-billion dollar market for ATTR-CM treatments. Multiple pharmaceutical companies are currently competing to develop and commercialize new therapies for the condition, and this setback could signal potential challenges for the entire drug class.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.
Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.
Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.
DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.